Association of miR-1266 with Recurrence/Metastasis Potential in Estrogen Receptor Positive Breast Cancer Patients

  • Sevinc, Elif Demirdogen (Department of Medical Biology, Faculty of Medicine, University of Uludag) ;
  • Egeli, Unal (Department of Medical Biology, Faculty of Medicine, University of Uludag) ;
  • Cecener, Gulsah (Department of Medical Biology, Faculty of Medicine, University of Uludag) ;
  • Tezcan, Gulcin (Department of Medical Biology, Faculty of Medicine, University of Uludag) ;
  • Tunca, Berrin (Department of Medical Biology, Faculty of Medicine, University of Uludag) ;
  • Gokgoz, Sehsuvar (Department of General Surgery, Faculty of Medicine, University of Uludag) ;
  • Tasdelen, Ismet (Department of General Surgery, Faculty of Medicine, University of Uludag) ;
  • Tolunay, Sahsine (Department of Pathology, Faculty of Medicine, University of Uludag) ;
  • Evrensel, Turkkan (Department of Medical Oncology, Faculty of Medicine, University of Uludag)
  • Published : 2015.02.04


The Homeobox B13 (HOXB13):Interleukin 17 Receptor B (IL17BR) index of estrogen receptor (ER)-positive breast cancer (ER (+) BC) patients may be a potential biomarker of recurrence/ metastasis. However, effects of microRNA (miRNA) binding to the 3' untranslated region (3' UTR) of HOXB13 and IL17BR and its function on recurrence/metastasis in ER (+) BC remains elusive. The aims of this study were to determine the expression of miRNAs that bind to 3' UTR of HOXB13 and IL17BR in ER (+) BC patients and asess the effects of these miRNAs on recurrence/metastasis. The expression profiles of HOXB13 and IL17BR were evaluated using RT-PCR in tumors and normal tissue samples from 40 ER (+) BC patients. The expression level of 4 miRNAs, which were predicted to bind the 3' UTR of HOXB13 and IL17BR using TargetScan, and miRDB online databases, were further evaluated with RT-PCR. Our findings demonstrated that high miR-1266 levels might be significant prognostic factor for recurrence/metastasis occurrence (3.05 fold p=0.004) and tamoxifen response (3.90 fold; p=0.2514) in ER (+) BC cases. Although we suggest that modulation of miR-1266 expression may be an important mechanism underlying the chemoresistance of ER (+) BC, advanced studies and validation are required.


Supported by : Uludag University of Turkey


  1. Avci CB, Harman E, Dodurga Y, Susluer SY, Gunduz C (2013). Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev, 14, 765-8.
  2. Benson JR, Jatoi I, Keisch M, et al (2009). Early breast cancer. Lancet, 373, 1463-79.
  3. Chen L, Lu MH, Zhang D, et al (2014). miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death Dis, 5, 1034.
  4. Chen WX, Liu XM, Lv MM, et al (2014). Exosomes from drugresistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One, 9, 95240.
  5. Chen WX, Zhong SL, Ji MH, et al (2014). MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer. Tumour Biol, 35, 2883-92.
  6. Chen Y, Sun Y, Chen L, et al (2013). miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep, 7, 1579-84.
  7. Corcoran C, Rani S, Breslin S, et al (2014). miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer, 13, 71.
  8. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al (2008). HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res, 61, 8452-8.
  9. Ell B, Qiu Q, Wei Y, et al (2014). The miRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin. J Biol Chem, 289, 21888-95.
  10. Gan R, Yang Y, Yang X, et al (2014). Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther, 21, 290-6.
  11. Gao T, Han Y, Yu L, et al (2014). CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. PLoS One, 9, 91771.
  12. Girault I, Bieche I, Lidereau R (2006). Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas, 54, 342-51.
  13. Hoch RV, Thompson DA, Baker RJ, Weigel RJ (1999). GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer, 84, 122-8.<122::AID-IJC5>3.0.CO;2-S
  14. Hoffman Y, Bublik DR, Pilpel Y, Oren M (2014). miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ, 21, 302-9.
  15. Hutchinson L (2010). Breast cancer: challenges, controversies, breakthroughs. Nat Rev Clin Oncol, 7, 669-70.
  16. Jansen MP, Sieuwerts AM, Look MP, et al (2007). HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol, 25, 662-8.
  17. Jerevall PL, Brommesson S, Strand C, et al (2008). Exploring the two-gene ratio in breast cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat, 107, 225-34.
  18. Jiang L, He D, Yang D, et al (2014). MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Lett, 588, 2009-15.
  19. Kayani Mu, Kayani MA, Malik FA, Faryal R (2011). Role of miRNAs in breast cancer. Asian Pac J Cancer Prev, 12, 3175-80.
  20. Li JY, Zhang Y, Zhang et al (2012). Differential distribution of miR-20a and miR-20b may underly metastatic heterogeneity of breast cancers. Asian Pac J Cancer Prev, 13, 1901-6.
  21. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25, 402-8.
  22. Ma XJ, Hilsenbeck SG, Wang W, et al (2006). The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol, 24, 4611-9.
  23. Ma XJ, Salunga R, Dahiya S, et al (2008). A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res, 14, 2601-8.
  24. Ma XJ, Wang Z, Ryan PD, et al (2004). A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell, 5, 607-16.
  25. Ng CH, Pathy NB, Taib NA, et al (2014). Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers? Asian Pac J Cancer Prev, 15, 7959-64.
  26. Pedraza V, Gomez-Capilla JA, Escaramis G, et al (2010). Gene expression signatures in breast cancer Perez- distinguish phenotype characteristics, histologic subtypes, and tumor invasiveness. Cancer, 116, 486-96.
  27. Rivas LG, Jerez JM, Carmona R, et al (2014). A microRNA signature associated with early recurrence in breast cancer. PLoS One, 9, 91884.
  28. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
  29. Porter P (2008). “Westernizing” women's risks? Breast cancer in lower-income countries. N Engl J Med, 358, 213-6.
  30. Reddy SD, Pakala SB, Ohshiro K, Rayala SK, Kumar R (2009). MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Res, 69, 5639-42.
  31. Sand M, Skrygan M, Sand D, et al (2013). Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res, 351, 85-98.
  32. Sgroi DC (2009). The HOXB13:IL17BR gene-expression ratio: a biomarker providing information above and beyond tumor grade. Biomark Med, 3, 99-102.
  33. Tekiner TA, Basaga H (2013). Role of microRNA deregulation in breast cancer cell chemoresistance and stemness. Curr Med Chem, 20, 3358-69.
  34. Vendrell JA, Ghayad S, Ben-Larbi S, et al (2007). A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene, 26, 4656-67.
  35. Vetter G, Saumet A, Moes M, et al (2010). miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene, 29, 4436-48.
  36. Wang HJ, Guo YQ, Tan G, et al (2013). miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem, 114, 2248-57.
  37. Ward A, Shukla K, Balwierz A, et al (2014). MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol, 233, 368-79.
  38. Yan H, Wang S, Yu H, Zhu J, Chen C (2013). Molecular pathways and functional analysis of miRNA expression associated with paclitaxel-induced apoptosis in hepatocellular carcinoma cells. Pharmacology, 92, 167-74.
  39. Zhang MH, Man HT, Zhao XD, Dong N, Ma SL (2014). Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). Biomed Rep, 2, 41-52.
  40. Zhao L, Zhu S, Gao Y, Wang Y (2014). Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis. Tumour Biol, 35, 3113-7.

Cited by

  1. Predicting miRNA targets for head and neck squamous cell carcinoma using an ensemble method vol.33, pp.1, 2018,
  2. The Diverse Roles of microRNAs at the Host–Virus Interface vol.10, pp.8, 2018,
  3. A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data vol.8, pp.1, 2018,